Fig. 6
From: Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus
Synergistic in vivo antiviral effects by combination therapy. a Scheme of chemical administration of atglistatin and oseltamivir, either individually or in combination, twice daily for 4 consecutive days after challenge with 103 PFU of mouse-adapted IAV PR8 strain to mice (n = 16). b Survival rates (expressed as percentages) of IAV-challenged mice after treatment. c Scheme of chemical administration of atglistatin and remdesivir, either individually or in combination, twice daily for 4.5 consecutive days after challenge with 105 TCID50 of SARS-CoV-2 KCDC03 (closely related to early Chines strains), KDCA51463 (Alpha lineage with British variants), and KDCA55905 (Beta lineage with South African variants) to Syrian hamsters (n = 5). d Reduction in gross lung lesions in Syrian hamsters challenged with each strain by combination therapy with atglistatin and remdesivir. e Effect of treatments on the recovery of body weight in each group. f Effect of treatments on the reduction in clinical signs in each group. g–i Effect of combination therapy of atglistatin and remdesivir on the recovery of body weight in Syrian hamsters (n = 5) challenged with SARS-CoV-2 KCDC03 (g), KDCA51463 (h), and KDCA55905 (i). Results are presented as arithmetic means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001, one-way analysis of variance with Tukey’s correction for multiple comparisons
